Dipyridamole increases cardiovascular effects of regadenoson (adenosine A2A-receptor agonist). Risk of cardiovascular side effects may be increased during stress testing.
Source: NLP:dipyridamole
Regadenoson Interactions
Brand names: Regadenoson
Adenosine Receptor Agonist · Adenosine Receptor Agonists
Route: Intravenous
Contraindications
4 CONTRAINDICATIONS Do not administer regadenoson injection to patients with: • Second- or third-degree AV block, or • sinus node dysfunction unless these patients have a functioning artificial pacemaker [ see Warnings and Precautions (5.2) ]. Do not administer regadenoson injection to patients with: • Second- or third-degree AV block, or • sinus node dysfunction unless the patients have a functioning artificial pacemaker (4) .
Pregnancy & Breastfeeding
8.1 Pregnancy Risk Summary There are no available data on regadenoson injection use in pregnant women to inform a drug-associated risk. In animal reproduction studies, adverse developmental outcomes were observed with the administration of regadenoson to pregnant rats and rabbits during organogenesis only at doses that produced maternal toxicity ( see Data ). In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Animal Data Reproductive studies in rats showed that regadenoson doses 10 and 20 times the maximum recommended human dose (MRHD) based on body surface area caused reduced fetal body weights and significant ossification delays in fore- and hind limb phalanges and metatarsals; maternal toxicity also occurred at these doses. Skeletal variations were increased in all treated groups. In rabbits, maternal toxicity occurred at regadenoson doses administered during organogenesis at 4 times the MRHD; however, there were no teratogenic effects in offspring at this dose. At higher doses, 12 and 20 times the MRHD, maternal toxicity occurred along with increased embryo-fetal loss and fetal malformations.
6 interactions on record
Regadenoson + AminophyllineModerate
Methylxanthine that interferes with the vasodilation activity of regadenoson. Patients should avoid for at least 12 hours before administration, though it may be used to attenuate severe adverse reactions.
Source: NLP:regadenoson
Dipyridamole increases cardiovascular effects of regadenoson, an adenosine A2A-receptor agonist. Risk of cardiovascular side effects may be increased during testing.
Source: NLP:aspirin and dipyridamole
Dipyridamole increases the cardiovascular effects of regadenoson. Risk may be increased during testing if dipyridamole not held 48 hours prior.
Source: NLP:aspirin and extended-release dipyridamole
Regadenoson + CaffeineModerate
Methylxanthine that interferes with the vasodilation activity of regadenoson. Patients should avoid consumption for at least 12 hours before regadenoson administration.
Source: NLP:regadenoson
Regadenoson + TheophyllineModerate
Methylxanthine that interferes with the vasodilation activity of regadenoson. Patients should avoid consumption for at least 12 hours before regadenoson administration.
Source: NLP:regadenoson